Veracyte raises 2025 revenue guidance as Q3 revenue rises 14% to $131.9 million
Veracyte reported third-quarter 2025 results on November 4, 2025, with total revenue up 14% to $131.9 million and GAAP net income of $19.1 million, up from $15.2 million a year earlier. The company raised its full-year 2025 total revenue and testing revenue guidance, which signals higher expected sales for shareholders, though GAAP results included a $6.7 million loss tied to the deconsolidation of Veracyte SAS.
Key points
- Total revenue rose to $131.9 million from $115.9 million; testing revenue rose 17% to $127.8 million.
- GAAP net income was $19.1 million, or $0.24 per diluted share, versus $15.2 million, or $0.19, a year earlier; results included a $6.7 million loss from the deconsolidation of Veracyte SAS.
- Full-year 2025 total revenue guidance was raised to $506 million to $510 million from $496 million to $504 million.
- Adjusted EBITDA was $39.7 million, or 30.1% of revenue, compared with 23.6% a year earlier.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:54 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.